Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis

Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine kinase inhibitors (TKIs) show longer progression-free survival (PFS) than those treated with chemotherapy. However, developed EGFR-TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Tai-Huang, Chen, Hsiao-Ling, Chang, Hsiu-Mei, Wu, Chiou-Mei, Wu, Kuan-Li, Kuo, Chia-Yu, Wei, Po-Ju, Chen, Chin-Ling, Liu, Hui-Lin, Hung, Jen-Yu, Yang, Chih-Jen, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224666/
https://www.ncbi.nlm.nih.gov/pubmed/35743437
http://dx.doi.org/10.3390/jcm11123366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224666/
https://www.ncbi.nlm.nih.gov/pubmed/35743437
http://dx.doi.org/10.3390/jcm11123366

Ejemplares similares